S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?

Natera (NTRA) Stock Price, News & Analysis

$90.46
+0.46 (+0.51%)
(As of 03/27/2024 ET)
Today's Range
$87.89
$90.86
50-Day Range
$64.62
$92.90
52-Week Range
$36.90
$96.24
Volume
1.62 million shs
Average Volume
1.82 million shs
Market Capitalization
$10.92 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.36

Natera MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.92 Rating Score
Upside/​Downside
13.4% Downside
$78.36 Price Target
Short Interest
Healthy
6.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.02mentions of Natera in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$26.21 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.43) to ($1.01) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.06 out of 5 stars

Medical Sector

589th out of 939 stocks

Medical Laboratories Industry

13th out of 19 stocks

NTRA stock logo

About Natera Stock (NASDAQ:NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

NTRA Stock Price History

NTRA Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Natera (NASDAQ:NTRA) Hits New 52-Week High at $96.24
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
NTRA Apr 2024 90.000 put
NTRA Apr 2024 87.500 call
NTRA Apr 2024 80.000 put
NTRA Mar 2024 82.500 call
NTRA Oct 2024 97.500 call
Natera Full Year 2023 Earnings: Beats Expectations
Decoding Natera Inc (NTRA): A Strategic SWOT Insight
Natera to Participate in March Investor Conferences
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/27/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Medical laboratories
Sub-Industry
N/A
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
3,293
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$78.36
High Stock Price Target
$110.00
Low Stock Price Target
$48.00
Potential Upside/Downside
-13.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.92
Research Coverage
13 Analysts

Profitability

Net Income
$-434,800,000.00
Pretax Margin
-40.14%

Debt

Sales & Book Value

Annual Sales
$1.08 billion
Book Value
$6.37 per share

Miscellaneous

Free Float
109,383,000
Market Cap
$10.92 billion
Optionable
Optionable
Beta
1.39
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

NTRA Stock Analysis - Frequently Asked Questions

Should I buy or sell Natera stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Natera in the last year. There are currently 1 hold rating and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NTRA shares.
View NTRA analyst ratings
or view top-rated stocks.

What is Natera's stock price target for 2024?

13 Wall Street research analysts have issued 1 year target prices for Natera's stock. Their NTRA share price targets range from $48.00 to $110.00. On average, they anticipate the company's stock price to reach $78.36 in the next year. This suggests that the stock has a possible downside of 13.4%.
View analysts price targets for NTRA
or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2024?

Natera's stock was trading at $62.64 at the beginning of the year. Since then, NTRA shares have increased by 44.4% and is now trading at $90.46.
View the best growth stocks for 2024 here
.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our NTRA earnings forecast
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) released its earnings results on Wednesday, February, 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.09. The medical research company had revenue of $311.11 million for the quarter, compared to analyst estimates of $300.38 million. Natera had a negative trailing twelve-month return on equity of 62.19% and a negative net margin of 40.16%.

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?
When did Natera IPO?

Natera (NTRA) raised $101 million in an initial public offering on Thursday, July 2nd 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray served as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

Who are Natera's major shareholders?

Natera's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.13%), Vanguard Group Inc. (9.09%), RTW Investments LP (2.16%), Kynam Capital Management LP (2.00%), Principal Financial Group Inc. (1.42%) and Norges Bank (1.12%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, John Fesko, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends
.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NTRA) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners